![](/img/cover-not-exists.png)
Short‐term cost‐utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events – a Canadian setting (DEVOTE 9)
Pollock, Richard F, Heller, Simon, Pieber, Thomas R, Woo, Vincent, Gundgaard, Jens, Hallén, Nino, Luckevich, Maria, Tutkunkardas, Deniz, Zinman, BernardLanguage:
english
Journal:
Diabetes, Obesity and Metabolism
DOI:
10.1111/dom.13730
Date:
March, 2019
File:
PDF, 835 KB
english, 2019